– USA, CA – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the appointment of Dr. Martine Zimmermann (PharmD) to its Board as an Independent Director, bringing 25 years of global experience in the pharmaceutical industry to the board.
“We are very pleased to welcome Martine to our board of directors. She brings considerable expertise in development and regulatory affairs at a global level, having held senior roles in which she provided strategic regulatory direction on all phases of drug development and across multiple therapeutic areas. This skill set will be invaluable as we build our portfolio of partnered programs,” said Board Chairman, Dr. John Kozarich.
About Dr. Martine Zimmermann
Dr. Martine Zimmermann has extensive expertise in regulatory affairs at both small and large pharmaceutical organizations, having worked in the United States, Europe, and Asia-Pacific. Throughout her career she has been involved in all phases of drug development and several therapeutic areas, interacting with relevant regulatory authorities in key markets, including the U.S. Food and Drug Administration, the European Medicines Agency, and the Japanese Pharmaceuticals and Medical Devices Agency. Dr. Zimmermann is currently SVP of Head of Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals, a global biopharmaceutical company. Before Ipsen, Dr. Zimmermann spent 13 years at Alexion Pharma International where she held several positions including SVP and Head of Global Regulatory Affairs. She is an active member of several life-sciences trade associations and was a member of the Board of Directors of Caelum Biosciences from 2019 until its acquisition by AstraZeneca in 2021. She has been a board member of France-based Inventiva (Euronext Paris and Nasdaq: IVA) since 2021.
Dr. Zimmermann received her Doctorate in Pharmacy with a specialty in immunology from the Louis Pasteur University, Strasbourg France.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies, or both. Our business model generates value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid to late-stage drug development in return for economic rights and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management, and commercialization) to generate our revenue. Our Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. We have established multiple alliances, licenses, and, other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International.
SOURCE: https://www.ligand.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
